MCID: MCN001
MIFTS: 48

Mucinous Adenocarcinoma

Categories: Cancer diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Mucinous Adenocarcinoma

MalaCards integrated aliases for Mucinous Adenocarcinoma:

Name: Mucinous Adenocarcinoma 11 14 71
Mucin-Producing Adenocarcinoma 11 71
Pseudomyxoma Peritonei with Unknown Primary Site 11
Mucin-Secreting Adenocarcinoma 11
Mucin-Secreting Carcinoma 11
Adenocarcinoma, Mucinous 43
Mucous Carcinoma 11

Classifications:



External Ids:

Disease Ontology 11 DOID:3030
MeSH 43 D002288
SNOMED-CT 68 72495009 900006
UMLS 71 C0007130 C0334368

Summaries for Mucinous Adenocarcinoma

Disease Ontology: 11 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which produce mucin.

MalaCards based summary: Mucinous Adenocarcinoma, also known as mucin-producing adenocarcinoma, is related to cervical mucinous adenocarcinoma and bile duct mucinous adenocarcinoma. An important gene associated with Mucinous Adenocarcinoma is CHST4 (Carbohydrate Sulfotransferase 4), and among its related pathways/superpathways are Disease and TCR Signaling (Qiagen). The drugs Irinotecan and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and lung, and related phenotypes are Increased cell migration and Synthetic lethal with vaccinia virus (VACV) infection

Related Diseases for Mucinous Adenocarcinoma

Diseases related to Mucinous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 779)
# Related Disease Score Top Affiliating Genes
1 cervical mucinous adenocarcinoma 32.6 NAPSA MUC6 KRT7
2 bile duct mucinous adenocarcinoma 32.6 TP53 MUC5AC
3 ovarian mucinous adenocarcinoma 32.5 MUC5AC KRT7 KRT20 CHST4 CEACAM5 CDX2
4 appendix adenocarcinoma 32.4 TP53 MSH6 KRT7 KRT20 KRAS HRAS
5 pseudomyxoma peritonei 31.9 TP53 MUC6 MUC5AC KRT7 KRT20 KRAS
6 renal pelvis adenocarcinoma 31.1 KRT7 CEACAM5
7 thymus adenocarcinoma 31.0 KRT20 CEACAM5 CDX2
8 appendiceal neoplasm 30.9 KRT7 KRAS HRAS CEACAM5 CDX2
9 intestinal obstruction 30.9 KRT7 KRT20 CEACAM5 CDX2
10 bladder adenocarcinoma 30.9 TP53 NAPSA KRT7 KRT20 CEACAM5 CDX2
11 pancreatic adenocarcinoma 30.8 TP53 KRAS HRAS ERBB2 EGFR
12 anus adenocarcinoma 30.8 MUC5AC KRT7 CDX2
13 benign teratoma 30.8 TP53 NKX2-1 KRT7 KRT20 CEACAM5 CDX2
14 cystic teratoma 30.8 TP53 NKX2-1 KRT7 KRT20 CEACAM5 CDX2
15 colon adenocarcinoma 30.8 TP53 MSH6 MLH1 KRT20 KRAS HRAS
16 anal canal adenocarcinoma 30.8 MUC5AC KRT7 KRT20 CDX2
17 cervical adenocarcinoma 30.8 TP53 MUC5AC KRT7 KRT20 KRAS CEACAM5
18 mammary paget's disease 30.7 KRT7 KRT20 ERBB2 CEACAM5
19 neuroendocrine carcinoma 30.7 NKX2-1 KRT7 KRT20
20 cystadenocarcinoma 30.7 TP53 MUC5AC KRT7 KRAS CEACAM5
21 thymic carcinoma 30.7 NKX2-1 KRT7 EGFR
22 vulva adenocarcinoma 30.7 KRT7 KRT20 ERBB2 CEACAM5 CDX2
23 clear cell adenocarcinoma 30.7 TP53 NAPSA KRT7
24 peutz-jeghers syndrome 30.7 TP53 MUC6 MUC5AC EGFR
25 suppression of tumorigenicity 12 30.7 TP53 HRAS ERBB2 EGFR
26 ovary adenocarcinoma 30.6 TP53 MLH1 KRT7 KRAS HRAS ERBB2
27 bladder urachal carcinoma 30.6 KRT7 KRAS HRAS CDX2
28 teratoma 30.6 TP53 NKX2-1 KRT7 KRT20 KRAS ERBB2
29 diffuse gastric cancer 30.6 TP53 PMS2 MSH6 MSH2 MLH1 KRAS
30 cystadenoma 30.6 MUC6 MUC5AC KRT7 KRT20 CEACAM5
31 cystitis 30.6 TP53 KRT7 KRT20
32 mucoepidermoid carcinoma 30.6 MUC5AC KRT7 EGFR
33 adenocarcinoma 30.5 TP53 NKX2-1 NAPSA MUC5AC MSH6 MSH2
34 endometrial adenocarcinoma 30.5 TP53 PMS2 MSH6 MSH2 MLH1 KRT7
35 rectum cancer 30.5 TP53 MSH6 MSH2 MLH1 KRT20 KRAS
36 mature teratoma 30.5 TP53 KRT7 CEACAM5 CDX2
37 benign mesothelioma 30.4 NKX2-1 KRT7 KRT20 CEACAM5
38 lobular neoplasia 30.4 TP53 ERBB2 EGFR
39 mucinous lung adenocarcinoma 30.4 NKX2-1 NAPSA KRAS HRAS EGFR ALK
40 cholecystitis 30.4 TP53 MUC6 MUC5AC EGFR
41 vulva cancer 30.4 TP53 KRT7 HRAS ERBB2 EGFR CEACAM5
42 transverse colon cancer 30.4 PMS2 MLH1 KRT20 KRAS HRAS CEACAM5
43 nephrogenic adenoma 30.4 NAPSA KRT7
44 endocervical adenocarcinoma 30.3 TP53 MUC6 MSH6 KRT7 HRAS ERBB2
45 esophagus adenocarcinoma 30.3 TP53 ERBB2 EGFR CDX2
46 blastoma 30.3 TP53 NKX2-1 KRT7 KRAS HRAS EGFR
47 papillary carcinoma 30.3 NKX2-1 KRT7 KRT20 ERBB2
48 struma ovarii 30.3 NKX2-1 KRT7 KRAS
49 ovarian germ cell cancer 30.3 NKX2-1 KRT7 CEACAM5
50 papillary cystadenocarcinoma 30.3 TP53 KRT7 KRT20

Graphical network of the top 20 diseases related to Mucinous Adenocarcinoma:



Diseases related to Mucinous Adenocarcinoma

Symptoms & Phenotypes for Mucinous Adenocarcinoma

GenomeRNAi Phenotypes related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell migration GR00055-A-1 9.26 NEK8
2 Increased cell migration GR00055-A-3 9.26 NEK8
3 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 8.62 MSH6 NEK8

MGI Mouse Phenotypes related to Mucinous Adenocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 ALK CDX2 CEACAM5 EGFR ERBB2 HRAS
2 neoplasm MP:0002006 10.25 ALK CDX2 CEACAM5 EGFR ERBB2 HRAS
3 digestive/alimentary MP:0005381 10.13 CDX2 CEACAM5 EGFR ERBB2 HRAS KRAS
4 endocrine/exocrine gland MP:0005379 10.11 ALK CDX2 CEACAM5 EGFR ERBB2 HRAS
5 cellular MP:0005384 10.07 CDX2 CEACAM5 CHST4 EGFR ERBB2 KRAS
6 respiratory system MP:0005388 9.81 ALK EGFR ERBB2 HRAS KRAS MLH1
7 mortality/aging MP:0010768 9.8 ALK CDX2 CEACAM5 EGFR ERBB2 HRAS
8 integument MP:0010771 9.28 ALK EGFR ERBB2 HRAS KRAS MLH1

Drugs & Therapeutics for Mucinous Adenocarcinoma

Drugs for Mucinous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
2
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
3
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
4
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 11947679 6857599
5
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
6
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
7
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
8
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
9
Camptothecin Experimental Phase 3 7689-03-4 24360
10
Edrecolomab Investigational Phase 3 156586-89-9
11
Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
12 Carotenoids Phase 3
13 topoisomerase I inhibitors Phase 3
14 Formyltetrahydrofolates Phase 3
15 Tetrahydrofolates Phase 3
16 Adjuvants, Immunologic Phase 3
17 Immunoglobulins, Intravenous Phase 3
18 Albumin-Bound Paclitaxel Phase 3
19 Immunoglobulin G Phase 3
20 Antimitotic Agents Phase 3
21 Tubulin Modulators Phase 3
22 Antibodies, Monoclonal Phase 3
23 Antineoplastic Agents, Immunological Phase 3
24 Angiogenesis Inhibitors Phase 3
25 Endothelial Growth Factors Phase 3
26 Mitogens Phase 3
27 Trace Elements Phase 3
28 Micronutrients Phase 3
29 Cola Phase 3
30 Taxane Phase 3 108169
31 Vitamins Phase 3
32 Hormones Phase 3
33 Calcium, Dietary Phase 3
34 Hematinics Phase 3
35
Calcium Nutraceutical Phase 3 7440-70-2 271
36
Panitumumab Approved, Investigational Phase 2 339177-26-3
37
Cetuximab Approved Phase 2 205923-56-4
38
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
39
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
40
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
41
Nintedanib Approved Phase 2 656247-17-5 135423438 9809715
42
Durvalumab Approved, Investigational Phase 2 1428935-60-7
43
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60699 60700
44
Olaparib Approved Phase 2 763113-22-0 23725625
45
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
46
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
47
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
48
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
49
Acetylcysteine Approved, Investigational Phase 2 616-91-1 581 12035
50
Nivolumab Approved Phase 2 946414-94-4

Interventional clinical trials:

(show top 50) (show all 69)
# Name Status NCT ID Phase Drugs
1 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
2 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
3 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Completed NCT00951496 Phase 3 Carboplatin;Cisplatin;Paclitaxel
4 A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
5 Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients With Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil Completed NCT00068692 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
6 Phase III Randomized Study of Adjuvant Immunotherapy With Monoclonal Antibody 17-1A Versus No Adjuvant Therapy Following Resection for State II (Modified Astler-Coller B2) Adenocarcinoma of the Colon Completed NCT00002968 Phase 3
7 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
8 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
9 GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262 Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
10 A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
11 A Phase II Study of the Combination of Aflibercept (VEGF-Trap) Plus Modified FOLFOX 6 in Patients With Previously Untreated Metastatic Colorectal Cancer Unknown status NCT01652196 Phase 2 oxaliplatin;leucovorin;fluorouracil
12 A Phase II Study of Panitumumab in Combination With FOLFIRI After Progression on FOLFIRI Plus Bevacizumab in KRAS(Kirsten Rat Sarcoma) and NRAS Wild-Type Metastatic Colorectal Cancer. Unknown status NCT01814501 Phase 2 irinotecan hydrochloride;fluorouracil;leucovorin calcium
13 A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC) Unknown status NCT04446091 Phase 1, Phase 2 Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.);Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan
14 Is Greater Downstaging and Tumour Regression Observed When Surgery is Delayed to 12 Weeks After Completion of Chemoradiotherapy vs 6 Weeks? Unknown status NCT01037049 Phase 2
15 A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma Completed NCT01097746 Phase 2 Carboplatin;Paclitaxel
16 A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
17 A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT02853318 Phase 2 Cyclophosphamide
18 A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation Completed NCT01802320 Phase 2 Akt Inhibitor MK2206
19 A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT02923739 Phase 2 Paclitaxel
20 A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00888173 Phase 2 Brivanib Alaninate
21 Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer Completed NCT00100841 Phase 2 oxaliplatin;leucovorin calcium;fluorouracil
22 A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01642082 Phase 2
23 A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01225887 Phase 2 Nintedanib
24 A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab Recruiting NCT04739800 Phase 2 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
25 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
26 Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
27 MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer Recruiting NCT02364713 Phase 2 Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
28 A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma Recruiting NCT05112601 Phase 2
29 METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin Recruiting NCT05504252 Phase 2 Nivolumab;Oxaliplatin
30 A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors Recruiting NCT02978625 Phase 2
31 Phase II Trial Of Neoadjuvant Bevacizumab With Modified FOLFOX7 In Patients With Stage II And III Rectal Cancer Active, not recruiting NCT01871571 Phase 2 oxaliplatin;leucovorin calcium;fluorouracil
32 A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus Active, not recruiting NCT00492778 Phase 2 Cisplatin
33 A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies Active, not recruiting NCT03602079 Phase 1, Phase 2 A166
34 A Phase 2, Multi-centre Study of BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei Not yet recruiting NCT03976973 Phase 2 Bromelain;Acetylcysteine
35 Randomized Phase II Trial Evaluating Compliance With Monitoring Conducted Either by a Hospital-based Physician in Person or by a Nurse in Remote Monitoring Not yet recruiting NCT05500391 Phase 2
36 A Phase II Study of Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors Terminated NCT03693846 Phase 2 Nivolumab;Ipilimumab
37 A Phase II Trial Of IRESSA (NSC 715055, IND 61187) In Combination With 5-FU/LV/ CPT-11 In Patients With Advanced Or Recurrent Colorectal Cancer Terminated NCT00052585 Phase 2 irinotecan hydrochloride;gefitinib;leucovorin calcium;fluorouracil
38 Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate, Indomethacin and Recombinant Human Interferon-Gamma in Advanced Colorectal Cancer Terminated NCT00002796 Phase 1, Phase 2 fluorouracil;sodium phenylbutyrate;indomethacin
39 A Randomized Double Blinded Study of Curcumin With Pre-operative Capecitabine and Radiation Therapy Followed by Surgery for Rectal Cancer Terminated NCT00745134 Phase 2 Capecitabine
40 Phase II Study of Ziv-Aflibercept Followed by the Addition of 5-FU in the Third Line Setting of Metastatic Colorectal Cancer Withdrawn NCT02235324 Phase 2 leucovorin calcium;fluorouracil
41 Phase I Study of the Combination of Irinotecan and MLN8237 in Advanced Solid Tumors With Emphasis on Colorectal Cancer Completed NCT01923337 Phase 1 irinotecan hydrochloride;alisertib
42 A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies Completed NCT01643499 Phase 1 oxaliplatin;irinotecan hydrochloride;leucovorin calcium;fluorouracil
43 A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
44 A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239) and Carboplatin (NSC# 241240) in Patients With Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
45 A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer Completed NCT00060411 Phase 1 erlotinib hydrochloride;fluorouracil;leucovorin calcium;oxaliplatin
46 Phase I Trial of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy With Nanoliposomal Irinotecan in Patients With Peritoneal Surface Malignancies Completed NCT04088786 Phase 1 nanoliposomal irinotecan
47 Phase I Study of Neoadjuvant Short Course Radiotherapy Concurrent With Infusional 5-Fluorouracil for the Treatment of Locally Advanced Rectal Cancer Completed NCT02270606 Phase 1 fluorouracil;oxaliplatin;leucovorin calcium
48 Phase I Study of Preoperative Radiation Therapy With Concurrent Protracted Continuous Infusion 5-FU and Dose Escalating Oxaliplatin Followed by Surgery, 5-FU, and Leucovorin for Locally Advanced (T3 and T4) Rectal Adenocarcinoma Completed NCT00003799 Phase 1 fluorouracil;oxaliplatin;leucovorin calcium
49 Pilot and Translational Study of Dasatinib (NSC#732517) Paclitaxel and Carboplatin in Women With Advanced Stage and Recurrent Endometrial Cancer Completed NCT01440998 Phase 1 Carboplatin;Dasatinib;Paclitaxel
50 Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex) Recruiting NCT02020707 Phase 1 Nab-paclitaxel

Search NIH Clinical Center for Mucinous Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, mucinous

Genetic Tests for Mucinous Adenocarcinoma

Anatomical Context for Mucinous Adenocarcinoma

Organs/tissues related to Mucinous Adenocarcinoma:

MalaCards : Colon, Liver, Lung, Appendix, Lymph Node, Prostate, Ovary

Publications for Mucinous Adenocarcinoma

Articles related to Mucinous Adenocarcinoma:

(show top 50) (show all 2715)
# Title Authors PMID Year
1
A massive malignant pleural effusion due to lung adenocarcinoma in an adult male: a case report. 62
36439928 2023
2
Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS). 62
36367122 2022
3
Establishment and Validation of a Novel Nomogram for Predicting Distant Metastasis in Patients with Invasive Lung Adenocarcinoma. 62
36474376 2022
4
Prognosis of resected invasive mucinous adenocarcinoma compared with the IASLC histologic grading system for invasive nonmucinous adenocarcinoma: Surgical database study in the TKIs era in Korea. 62
36345148 2022
5
High Rate of Positive Circumferential Resection Margin in Colon Cancer: A National Appraisal and Call for Action. 62
33630474 2022
6
Breast metastasis of signet ring cell carcinoma from the colon: a case report. 62
36451153 2022
7
Adult Colo-Colonic Intussusception in the Setting of Invasive Mucinous Adenocarcinoma: A Case Report. 62
36464886 2022
8
Mixed neuroendocrine/Non-neuroendocrine neoplasm (MiNEN) of gastrointestinal lineage arising in an ovarian mature cystic teratoma. 62
36388757 2022
9
NKX3.1 Expression in Salivary Gland "Intraductal" Papillary Mucinous Neoplasm: A Low-Grade Subtype of Salivary Gland Mucinous Adenocarcinoma. 62
35834096 2022
10
Targeted molecular profiling of salivary duct carcinoma with rhabdoid features highlights parallels to other apocrine and discohesive neoplasms: which phenotype should drive classification? 62
35794510 2022
11
Appendiceal mucinous adenocarcinoma masquerading as acute appendicitis. 62
35732542 2022
12
Pneumonic-type invasive mucinous adenocarcinoma and infectious pneumonia: clinical and CT imaging analysis from multiple centers. 62
36461012 2022
13
MUC6 distribution in the spectrum of pulmonary mucinous adenocarcinoma. 62
36071099 2022
14
Next generation sequencing targeted detection of somatic mutations in patients with mucinous adenocarcinoma of the appendix. 62
36122512 2022
15
Defining the spatial landscape of KRAS mutated congenital pulmonary airway malformations: a distinct entity with a spectrum of histopathologic features. 62
35794233 2022
16
Prevention of radiation enteritis by interposition of an intra-abdominal spacer before irradiation of an appendiceal tumour abscess drainage route. 62
35853802 2022
17
Clinicopathological and genetic analyses of pulmonary enteric adenocarcinoma. 62
36456172 2022
18
Tumor Depth Prediction of Gastric Cancer With a T4 Score. 62
36340460 2022
19
The Association of R-Loop Binding Proteins Subtypes with CIN Implicates Therapeutic Strategies in Colorectal Cancer. 62
36428700 2022
20
Lymph node metastasis in T1 colorectal cancer with the only high-risk histology of submucosal invasion depth ≥ 1000 μm. 62
36283994 2022
21
Neonatal congenital pulmonary airway malformation associated with mucinous adenocarcinoma and KRAS mutations. 62
34980466 2022
22
A refined prediction of early recurrence combining tumor deposits in patients with resected rectal mucinous adenocarcinoma. 62
36357597 2022
23
Clinical outcomes and patterns of population-based management of urachal carcinoma of the bladder: An analysis of the National Cancer Database. 62
35509235 2022
24
Proposal of a revised International Association for the Study of Lung Cancer grading system in pulmonary non-mucinous adenocarcinoma: The importance of the lepidic proportion. 62
36436241 2022
25
A prognostic nomogram for predicting overall survival in colorectal mucinous adenocarcinoma patients based on the SEER database. 62
36373623 2022
26
[A tumor of the uterus with a falsely benign aspect]. 62
35034828 2022
27
Colonic mucinous adenocarcinoma in a tufted deer: differential diagnosis and literature review. 62
36056527 2022
28
The appendix "mucocoele" misnomer: radiological terminology of "likely appendix mucinous neoplasm" better reflects pathology findings. 62
36411089 2022
29
Cystic Salivary Gland Neoplasms: Diagnostic Approach With a Focus on Ancillary Studies. 62
36044380 2022
30
The therapeutic efficacy of radical prostatectomy and external beam radiation therapy in patients with different pathological patterns of prostate cancer. 62
36376185 2022
31
Invasive Mucinous Adenocarcinoma of the Lung With a Mural Nodule-like Lesion. 62
35939825 2022
32
Correlation of clinical, pathologic, and genetic parameters with intratumoral immune milieu in mucinous adenocarcinoma of the colon. 62
35590108 2022
33
Extramural venous invasion and depth of extramural invasion on preoperative CT as prognostic imaging biomarkers in patients with locally advanced ascending colon cancer. 62
36066635 2022
34
Validation Study of New IASLC Histology Grading System in Stage I Non-Mucinous Adenocarcinoma Comparing With Minimally Invasive Adenocarcinoma. 62
35945128 2022
35
A Case of Invasive Mucinous Adenocarcinoma with Acute Respiratory Distress Syndrome Diagnosed by Autopsy Findings. 62
36418103 2022
36
[Relationship of diffusion kurtosis imaging parameters with the pathologic type and prognosis of rectal tumors]. 62
36380670 2022
37
Retroperitoneal mass, a rare manifestation of mucinous adenocarcinoma of appendix: A case report. 62
36415704 2022
38
Mucinous histology is associated with poor prognosis in locally advanced colorectal adenocarcinoma treated with postoperative first-line adjuvant chemotherapy: A systematic review and meta-analysis. 62
35768312 2022
39
Molecular Evidence for Epithelial Origin of Mixed Ovarian Epithelial-Germ Cell Neoplasms: Report of 2 Cases and Review of Literature. 62
36305517 2022
40
The clinicopathological and prognostic significances of CDC73 expression in breast cancer: A pathological and bioinformatics analysis. 62
36255176 2022
41
Mucinous adenocarcinoma of the prostatic urethra after brachytherapy for prostatic adenocarcinoma: a case series. 62
35926810 2022
42
Mucinous adenocarcinoma arising from a tailgut cyst: A case report. 62
36337315 2022
43
Locally advanced rectal mucinous adenocarcinoma: is preoperative radiation necessary? 62
36388693 2022
44
Diffusion-Weighted MRI as Non-Invasive Diagnostic Tool for Rectal Cancer Aggressiveness and Correlation with KI-67 Expression in Tumor Tissue. 62
36308363 2022
45
Quantitative T2 Mapping to Discriminate Mucinous from Nonmucinous Adenocarcinoma in Rectal Cancer: Comparison with Diffusion-weighted Imaging. 62
34421090 2022
46
Bronchorrhea, a Rare and Debilitating Symptom of Lung Cancer: Case Report and Review of the Treatment. 62
36164316 2022
47
Retroperitoneal primary adenocarcinoma of Mullerian origin: case report with radiology review. 62
35965919 2022
48
Development and validation of a prognostic nomogram for patients with stage II colon mucinous adenocarcinoma. 62
36149446 2022
49
Establishment and validation of a postoperative predictive model for patients with colorectal mucinous adenocarcinoma. 62
36192778 2022
50
The long-term outcome following thoraco-amniotic shunting for congenital lung malformations. 62
36379747 2022

Variations for Mucinous Adenocarcinoma

Expression for Mucinous Adenocarcinoma

Search GEO for disease gene expression data for Mucinous Adenocarcinoma.

Pathways for Mucinous Adenocarcinoma

Pathways related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.64 ALK EGFR ERBB2 HRAS KRAS MLH1
2
Show member pathways
12.89 TP53 MSH6 MSH2 MLH1 KRAS HRAS
3 12.79 KRAS HRAS ERBB2 EGFR ALK
4
Show member pathways
12.5 TP53 MSH2 KRAS HRAS ERBB2 EGFR
5
Show member pathways
12.4 EGFR ERBB2 HRAS KRAS TP53
6
Show member pathways
12.39 MUC6 MUC5AC KRAS HRAS
7
Show member pathways
12.39 EGFR ERBB2 HRAS KRAS TP53
8
Show member pathways
12.38 PMS2 MSH6 MSH2 MLH1
9 12.36 TP53 KRAS HRAS EGFR
10
Show member pathways
12.36 TP53 KRAS HRAS ERBB2 EGFR
11
Show member pathways
12.35 KRAS HRAS ERBB2 EGFR ALK
12
Show member pathways
12.22 KRAS HRAS ERBB2 EGFR
13
Show member pathways
12.17 TP53 KRAS HRAS ERBB2 EGFR
14
Show member pathways
12.13 EGFR ERBB2 HRAS KRAS
15 12.06 TP53 KRAS ERBB2 EGFR
16
Show member pathways
12.03 KRAS HRAS ERBB2 EGFR
17 12.03 TP53 MSH6 MSH2 KRAS EGFR
18
Show member pathways
12 KRAS HRAS ERBB2 EGFR
19
Show member pathways
11.93 KRAS HRAS ERBB2 EGFR
20 11.91 TP53 PMS2 MSH2 MLH1 EGFR
21
Show member pathways
11.9 TP53 MSH6 MSH2 MLH1 KRAS HRAS
22 11.85 TP53 MSH6 MSH2 MLH1 KRAS EGFR
23 11.83 TP53 KRAS HRAS ERBB2
24
Show member pathways
11.78 TP53 MSH6 MSH2
25 11.76 TP53 MSH2 MLH1
26
Show member pathways
11.74 HRAS KRAS TP53
27 11.63 TP53 HRAS ERBB2
28 11.53 KRAS HRAS ERBB2 EGFR
29 11.52 EGFR ERBB2 HRAS KRAS TP53
30 11.46 KRAS HRAS EGFR
31
Show member pathways
11.41 TP53 MSH2 MLH1
32 11.38 TP53 MSH6 MSH2
33 11.38 KRAS HRAS ALK
34 11.36 EGFR ERBB2 HRAS
35 11.25 TP53 KRAS HRAS EGFR
36 11.24 KRAS HRAS EGFR
37
Show member pathways
11.17 KRAS HRAS EGFR
38 11.13 PMS2 MSH6 MSH2 MLH1
39 11.07 KRAS HRAS ERBB2 EGFR
40 10.96 TP53 KRAS HRAS ERBB2 EGFR
41
Show member pathways
10.77 KRAS HRAS
42
Show member pathways
10.25 PMS2 MLH1

GO Terms for Mucinous Adenocarcinoma

Cellular components related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MutLalpha complex GO:0032389 9.46 PMS2 MLH1
2 MutSalpha complex GO:0032301 9.26 MSH6 MSH2
3 mismatch repair complex GO:0032300 9.02 PMS2 MSH2 MLH1

Biological processes related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 intrinsic apoptotic signaling pathway GO:0097193 9.93 TP53 MSH6 HRAS
2 determination of adult lifespan GO:0008340 9.91 TP53 MSH6 MSH2
3 regulation of cell population proliferation GO:0042127 9.91 ALK EGFR ERBB2 HRAS TP53
4 positive regulation of helicase activity GO:0051096 9.81 MSH6 MSH2
5 positive regulation of isotype switching to IgA isotypes GO:0048298 9.8 MSH2 MLH1
6 isotype switching GO:0045190 9.8 MSH6 MSH2 MLH1
7 mismatch repair GO:0006298 9.76 PMS2 MSH6 MSH2 MLH1
8 multicellular organism development GO:0007275 9.71 ERBB2 EGFR CDX2 ALK
9 maintenance of DNA repeat elements GO:0043570 9.65 MSH6 MSH2
10 positive regulation of miRNA maturation GO:1903800 9.52 TP53 EGFR
11 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.43 MSH2 MLH1
12 somatic recombination of immunoglobulin gene segments GO:0016447 9.35 MSH6 MSH2 MLH1
13 somatic hypermutation of immunoglobulin genes GO:0016446 9.23 PMS2 MSH6 MSH2 MLH1

Molecular functions related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 10.18 TP53 NKX2-1 MSH6 MSH2 MLH1 EGFR
2 double-stranded DNA binding GO:0003690 9.98 MSH6 MSH2 EGFR CDX2
3 nucleotide binding GO:0000166 9.91 NEK8 MSH6 MSH2 MLH1 KRAS HRAS
4 MutLalpha complex binding GO:0032405 9.78 MSH6 MSH2
5 oxidized purine DNA binding GO:0032357 9.76 MSH6 MSH2
6 ATP-dependent DNA damage sensor activity GO:0140664 9.76 PMS2 MSH6 MSH2 MLH1
7 single guanine insertion binding GO:0032142 9.67 MSH6 MSH2
8 single thymine insertion binding GO:0032143 9.62 MSH2 MSH6
9 guanine/thymine mispair binding GO:0032137 9.43 MSH6 MSH2 MLH1
10 mismatched DNA binding GO:0030983 9.1 PMS2 MSH6 MSH2 MLH1

Sources for Mucinous Adenocarcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....